The first one that lasted long enough
Liraglutide takes the human GLP-1 sequence, swaps one residue and attaches a sixteen-carbon fatty acid chain. That chain binds it to albumin, which slows clearance from minutes to roughly half a day.
Half a day was a breakthrough at the time and a limitation in hindsight. It made a once-daily injection possible where nothing had been possible before, and it set the target that the next generation had to beat.
The hormone this molecule copies lasts only a couple of minutes in circulation, because DPP-4 cuts it almost as soon as it appears. Every compound in the class is an answer to that clearance problem, and this one was the first answer durable enough to build a programme around.
Why weekly replaced daily
Semaglutide uses the same basic strategy with a longer, differently structured fatty diacid and an additional modification protecting the cleavage site. The result stretched the half-life from about thirteen hours to about a week.
Seven injections a year against three hundred and sixty-five is not a small difference in practice, and the head-to-head trials also favoured the weekly compound on the endpoints that mattered. The class moved on quickly.
Duration is not the only axis, though, and reading the sequence of compounds as a straight upgrade path loses something. Receptor engagement over time, tolerability at the exposures studied and the shape of the curve between doses all differ between the two molecules. A question about short exposure windows may genuinely be better served by the shorter compound.
| Class | GLP-1 receptor agonist |
| Modification | C16 fatty acid, albumin binding |
| Half-life | Approximately 13 hours |
| Dosing interval | Daily |
| Superseded by | Semaglutide |
| Stocked here | No, reference page |
| Closest product | Semaglutide research vial |
| Category | Research use only |
Bench data about the material. Nothing more is being claimed.
We do not supply liraglutide
It is documented here because people search for it, and because the comparison with semaglutide is the clearest illustration in this catalogue of what half-life engineering actually buys you.
If liraglutide is what brought you here, the semaglutide page covers the same receptor with a longer duration and a deeper trial record. That is the honest recommendation, and it is what we stock.
If you arrived here typing what is liraglutide into a search box, the short version is a modified GLP-1 sequence carrying a fatty acid chain, superseded rather than withdrawn. The longer version is spread across the weight and metabolism research area, where the incretin compounds are set out next to each other rather than one at a time.
What an approval does not transfer
Liraglutide is the active substance in medicines authorised in Europe, and the assessment behind those authorisations is public rather than proprietary. The European public assessment report sets out what the regulator reviewed, what it concluded and what it required afterwards.
What that record does not do is travel with the sequence. An authorised medicine is a particular formulation, made to a filed specification, carrying an indication that was argued for and granted. Research material with the same active peptide is a different object, covered by none of it, which is the whole point of the research use only classification rather than a piece of small print at the foot of the page.
The published literature is the second layer, and the larger one. The indexed work on PubMed returns the trial reports alongside the mechanistic studies, in enough volume that filtering by study type is worth doing before drawing any conclusion at all. Where a dual or triple agonist is the comparison you actually want, the tirzepatide page covers what adding receptors changes.
Liraglutide in the catalogue
Each batch is analysed by HPLC and released only at 99% or above.
Where Liraglutide fits in
Three pages to read alongside this one.
About Liraglutide
What we are asked about this compound most.